Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402166 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02402166 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 24 participants.
The verdict
NCT02402166, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD. Generating such data will provide data on the use of SPD489 in the preschool ADHD population.
Interventions
- DRUG SPD489
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-04-15 |
| Est. Completion | 2016-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02402166
The ClinicalTrials.gov registry entry for NCT02402166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPD489 is the first listed.
NCT02402166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02402166 about?
NCT02402166 is a clinical study titled "Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder". The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD. Generating such data will provide data on the use of SPD489 in the preschool ADHD population.
What is the current status of trial NCT02402166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-04-15. Estimated completion is 2016-06-30.
What interventions are being tested in trial NCT02402166?
The interventions under investigation include: SPD489 (DRUG).
Who is sponsoring clinical trial NCT02402166?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.